What is Teva?
Teva Pharmaceutical Industries Ltd. stands as a global biopharmaceutical leader dedicated to improving health outcomes. The company leverages a robust generics business to develop, manufacture, and distribute a wide array of medications, including complex generics, biosimilars, innovative therapies, and pharmacy brands. Teva's strategic focus is on addressing unmet patient needs through advanced scientific research, expanding access to essential medicines, and optimizing treatment delivery, from established generic options to novel therapeutic solutions.
How much funding has Teva raised?
Teva has raised a total of $99.3B across 28 funding rounds:
Multiple Rounds
$11.3B
Multiple Rounds
$7.6B
Debt
$2.4B
Debt
$33.8B
Multiple Rounds
$28.1B
Corporate Investment
$358M
Debt
$4.5B
Debt
$2.3B
Private Equity
$400M
Debt (2011): $1.5B backed by Citibank and HSBC Bank
Debt (2011): $750M with participation from Undisclosed
Debt (2011): $4B led by HSBC Bank
Debt (2011): $5B supported by BNP Paribas Securities Corp., Citigroup Global Markets, HSBC Securities, Barclays Capital, Morgan Stanley & Co., Goldman, Sachs & Co., Credi Suisse Securities, and JP Morgan Securities
Debt (2012): $1.2B featuring Undisclosed
Debt (2012): $946.9M backed by Undisclosed
Debt (2012): $495.2M with participation from Undisclosed
Debt (2012): $2B led by Barclays Capital, Goldman Sachs, JP Morgan Securities, and Morgan Stanley & Co.
Debt (2012): $3B supported by HSBC Bank and Citibank
Debt (2015): $2.4B featuring Undisclosed
Debt (2015): $33.8B backed by HSBC, Citi, Barclays Bank, Sumitomo Mitsui Banking Corporation, Credit Suisse, RBC Capital Markets, Mizuho Bank, BNP Paribas, Bank of America Merrill Lynch, and Morgan Stanley Senior Funding
Debt (2016): $7.2B with participation from Undisclosed
Debt (2016): $15B led by Undisclosed
Debt (2016): $4.7B supported by Undisclosed
Debt (2016): $1.1B featuring Undisclosed
Corporate Investment (2018): $358M backed by Warren Buffett
Debt (2018): $4.5B with participation from Undisclosed
Debt (2019): $2.3B led by Undisclosed
Private Equity (2026): $400M supported by Blackstone
Key Investors in Teva
Warren Buffett
Warren Buffett is a renowned investor, often associated with Berkshire Hathaway, known for his long-term investment strategies and significant capital allocations across various industries. His involvement suggests a strong belief in Teva's fundamental value and future growth potential.
Citibank
Citibank, a subsidiary of Citigroup, is a major global financial services institution providing a comprehensive suite of banking and financial products. Its participation indicates confidence in Teva's financial stability and strategic direction.
Deutsche Bank
Deutsche Bank is a leading global investment bank offering a wide range of financial services, including corporate and investment banking. Its involvement suggests a strategic financial partnership supporting Teva's large-scale funding requirements and market operations.
What's next for Teva?
The recent major strategic investment signals Teva's ongoing commitment to scaling its operations and advancing its pipeline. This capital will likely fuel further research and development into innovative therapies and complex generics, aiming to address critical unmet patient needs. Teva's strategy appears focused on consolidating its position in the global pharmaceutical landscape by enhancing its product offerings and expanding market reach, thereby reinforcing its role as a key provider of accessible and advanced medical treatments.
See full Teva company page
